Thalidomicle for treatment of severe intestinal bleeding

Gut

Volumn 53, Issue 4, 2004, Pages 609-612

  Bauditz, J ^a   Schachschal, G ^a   Wedel, S ^a   Lochs, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; BUDESONIDE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; PREDNISONE; TECHNETIUM 99M; ANGIOGENESIS INHIBITOR; THALIDOMIDE; VASCULOTROPIN A;

ADULT; AGED; ANGIODYSPLASIA; ANGIOGENESIS; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CROHN DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT OUTCOME; BLOOD; CASE REPORT; MIDDLE AGED; RECURRENT DISEASE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CROHN DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1642279661     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.029710     Document Type: Article

References (21)

1. Gordon FH, Watkinson A, Hodgson H. Vascular malformations of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2001;15:41-58.
2. Lewis BS, Kornbluth A, Waye JD. Small bowel tumours: yield of enteroscopy. Gut 1991;32:763-5.
3. van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990;335:953-5.
4. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001;121:1073-9.
5. Junquera F, Saperas E, de Torres I, et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999;94:1070-6.
6. Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn's disease. Ann Surg 1991;213:207-11.
7. Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn's disease. Report of seven cases and review of the literature. Arch Surg 1976;111:901-5.
8. Bauditz J, Wedel S, Lochs H. Thalidomide reduces TNFα and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;2:196-200.
9. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is on inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
10. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
11. Griga T, May B, Pfisterer O, et al. Immunohistochemical localization of vascular endothelial growth factor in colonic mucoso of patients with inflammatory bowel disease. Hepatogastroenterology 2002;49:116-23.
12. Griga T, Tromm A, Spranger J, et al. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:504-8.
13. Bousvaros A, Leichtner A, Zurakowski D, et al. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci 1999;44:424-30.
14. Ell C, Remke S, May A, et al. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy 2002;34:685-9.
15. Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-Amino-phthalimido- glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002;62:2300-5.
16. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically-active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
17. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial. Gastroenterology 1999;117:1271-7.
18. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
19. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003;98:221-2.
20. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
21. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-87.